Market Cap
US$2.9b
Last Updated
2021/03/01 23:45 UTC
Data Sources
Company Financials +
Executive Summary
Cabot Corporation operates as a specialty chemicals and performance materials company. More Details
Rewards
Risk Analysis
Snowflake Analysis
Reasonable growth potential average dividend payer.
Similar Companies
Share Price & News
How has Cabot's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CBT is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: CBT's weekly volatility (4%) has been stable over the past year.
Market Performance
7 Day Return
0.4%
CBT
-0.08%
US Chemicals
-1.3%
US Market
1 Year Return
31.3%
CBT
35.0%
US Chemicals
41.9%
US Market
Return vs Industry: CBT underperformed the US Chemicals industry which returned 36.4% over the past year.
Return vs Market: CBT underperformed the US Market which returned 36.5% over the past year.
Shareholder returns
| CBT | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.4% | -0.08% | -1.3% |
| 30 Day | 15.5% | 6.3% | 7.5% |
| 90 Day | 22.2% | 5.6% | 15.9% |
| 1 Year | 35.8%31.3% | 38.0%35.0% | 44.8%41.9% |
| 3 Year | -8.0%-16.1% | 33.4%13.0% | 49.1%41.0% |
| 5 Year | 21.5%5.9% | 96.3%57.4% | 113.1%92.8% |
Long-Term Price Volatility Vs. Market
How volatile is Cabot's share price compared to the market and industry in the last 5 years?
Simply Wall St News
6 days ago | Simply Wall St
When Should You Buy Cabot Corporation (NYSE:CBT)?3 months ago | Simply Wall St
We Wouldn't Be Too Quick To Buy Cabot Corporation (NYSE:CBT) Before It Goes Ex-Dividend3 months ago | Simply Wall St
We're Watching These Trends At Cabot (NYSE:CBT)Valuation
Is Cabot undervalued compared to its fair value and its price relative to the market?
6.8%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CBT ($50.71) is trading below our estimate of fair value ($54.41)
Significantly Below Fair Value: CBT is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: CBT is unprofitable, so we can't compare its PE Ratio to the US Chemicals industry average.
PE vs Market: CBT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CBT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CBT is overvalued based on its PB Ratio (3.5x) compared to the US Chemicals industry average (2.5x).
Next Steps
Future Growth
How is Cabot forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
62.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CBT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: CBT is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CBT's is expected to become profitable in the next 3 years.
Revenue vs Market: CBT's revenue is expected to decline over the next 3 years (-2.8% per year).
High Growth Revenue: CBT's revenue is forecast to decline over the next 3 years (-2.8% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CBT's Return on Equity is forecast to be high in 3 years time (24.8%)
Next Steps
Past Performance
How has Cabot performed over the past 5 years?
3.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CBT is currently unprofitable.
Growing Profit Margin: CBT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CBT is unprofitable, but has reduced losses over the past 5 years at a rate of 3.4% per year.
Accelerating Growth: Unable to compare CBT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CBT is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-1.4%).
Return on Equity
High ROE: CBT has a negative Return on Equity (-20.48%), as it is currently unprofitable.
Next Steps
Financial Health
How is Cabot's financial position?
Financial Position Analysis
Short Term Liabilities: CBT's short term assets ($1.1B) exceed its short term liabilities ($570.0M).
Long Term Liabilities: CBT's short term assets ($1.1B) do not cover its long term liabilities ($1.4B).
Debt to Equity History and Analysis
Debt Level: CBT's debt to equity ratio (100.9%) is considered high.
Reducing Debt: CBT's debt to equity ratio has increased from 79.9% to 100.9% over the past 5 years.
Debt Coverage: CBT's debt is well covered by operating cash flow (30.2%).
Interest Coverage: CBT is unprofitable, therefore interest payments are not well covered by earnings.
Balance Sheet
Next Steps
Dividend
What is Cabot current dividend yield, its reliability and sustainability?
2.76%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: CBT's dividend (2.76%) is higher than the bottom 25% of dividend payers in the US market (1.33%).
High Dividend: CBT's dividend (2.76%) is low compared to the top 25% of dividend payers in the US market (3.76%).
Stability and Growth of Payments
Stable Dividend: CBT's dividends per share have been stable in the past 10 years.
Growing Dividend: CBT's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: CBT is paying a dividend but the company is unprofitable.
Future Payout to Shareholders
Future Dividend Coverage: CBT's dividends in 3 years are forecast to be well covered by earnings (33.7% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.7yrs
Average management tenure
CEO
Sean Keohane (53 yo)
4.92yrs
Tenure
US$5,817,523
Compensation
Mr. Sean D. Keohane serves as Independent Director of Chemours Company since May 3, 2018. He has been the Chief Executive Officer and President of Cabot Corporation since March 11, 2016. He was a member of...
CEO Compensation Analysis
Compensation vs Market: Sean's total compensation ($USD5.82M) is about average for companies of similar size in the US market ($USD4.99M).
Compensation vs Earnings: Sean's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.92yrs | US$5.82m | 0.21% $ 6.1m | |
| Senior VP & CFO | 2.75yrs | US$1.50m | 0.022% $ 631.1k | |
| Senior VP & General Counsel | 1.67yrs | US$1.09m | 0.0067% $ 191.8k | |
| Senior VP | 8.83yrs | US$2.16m | 0.081% $ 2.3m | |
| Senior VP | 4.83yrs | US$1.44m | 0.083% $ 2.4m | |
| Senior VP & CTO | 3yrs | no data | no data | |
| VP of Investor Relations & Treasurer | 4.58yrs | no data | no data | |
| Corporate Communications Director | no data | no data | no data | |
| Senior VP & Chief Human Resources Officer | 3.83yrs | no data | no data | |
| Senior VP of Safety | 3.58yrs | no data | no data | |
| Senior VP & President of Formulated Solutions and President of The EMEA Region | 2.33yrs | no data | no data | |
| Senior VP & President of Purification Solutions Segment | no data | no data | no data |
3.7yrs
Average Tenure
50yo
Average Age
Experienced Management: CBT's management team is considered experienced (3.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.92yrs | US$5.82m | 0.21% $ 6.1m | |
| Independent Director | 0.83yr | US$117.52k | 0.0086% $ 246.0k | |
| Independent Director | 24.08yrs | US$220.60k | 0.084% $ 2.4m | |
| Independent Director | 6.42yrs | US$222.97k | 0.028% $ 791.8k | |
| Independent Director | 15.92yrs | US$217.99k | 0.0037% $ 106.5k | |
| Independent Director | 3.08yrs | US$210.00k | 0.017% $ 476.3k | |
| Independent Director | 8.58yrs | US$226.06k | 0.034% $ 977.3k | |
| Independent Non-Executive Chairman | 2.92yrs | US$320.00k | 0.038% $ 1.1m | |
| Independent Director | 2.42yrs | US$210.07k | 0.015% $ 422.0k | |
| Independent Director | 1.75yrs | US$210.03k | 0.012% $ 352.0k | |
| Independent Director | 3.42yrs | US$230.13k | 0.0035% $ 101.3k |
3.4yrs
Average Tenure
61yo
Average Age
Experienced Board: CBT's board of directors are considered experienced (3.4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Cabot Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Cabot Corporation
- Ticker: CBT
- Exchange: NYSE
- Founded: 1882
- Industry: Commodity Chemicals
- Sector: Materials
- Market Cap: US$2.871b
- Shares outstanding: 56.62m
- Website: https://www.cabotcorp.com
Number of Employees
Location
- Cabot Corporation
- Two Seaport Lane
- Suite 1400
- Boston
- Massachusetts
- 02210-2019
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CBT | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Aug 1968 |
| CBT | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Aug 1968 |
Biography
Cabot Corporation operates as a specialty chemicals and performance materials company. It operates through three segments: Reinforcement Materials, Performance Chemicals, and Purification Solutions. The co...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/03/01 23:45 |
| End of Day Share Price | 2021/03/01 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/09/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.